The potential feasibility of nab-paclitaxel as the first-line chemotherapy for ovarian cancer: clinical development and future perspectives
Author:
Funder
Beijing Xisike Clinical Oncology Research Founding
Publisher
Springer Science and Business Media LLC
Subject
Obstetrics and Gynecology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s00404-022-06425-3.pdf
Reference54 articles.
1. Reid BM, Permuth JB, Sellers TA (2017) Epidemiology of ovarian cancer: a review. Cancer Biol Med 14(1):9–32
2. Tsibulak I, Zeimet AG, Marth C (2019) Hopes and failures in front-line ovarian cancer therapy. Crit Rev Oncol Hematol 143:14–19
3. du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M et al. (2005) 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Annals of oncology: official journal of the European Society for Medical Oncology, pp viii7–viii12.
4. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R et al (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96(22):1682–1691
5. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E et al (2000) Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92(9):699–708
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Pathological response and safety of albumin-bound paclitaxel as a neoadjuvant treatment for HER2-positive breast cancer compared to docetaxel combined with anti-HER2 therapy: a real-world study;Frontiers in Oncology;2024-08-21
2. Drug Therapy and Progress in Advanced Epithelial Ovarian Cancer;Journal of Clinical Personalized Medicine;2024
3. Application of medical imaging in ovarian cancer: a bibliometric analysis from 2000 to 2022;Frontiers in Oncology;2023-12-04
4. Case report: Idiopathic pulmonary fibrosis induced by nab-paclitaxel: A rare complication;Frontiers in Pharmacology;2023-02-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3